Clinical trials: Diabetes Type II
Diabetes Mellitus, Type 1
Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus
Insulin lispro is approved by the Food and Drug Administration (FDA) for the treatment of diabetes mellitus. Recombinant human hyaluronidase (rHuPH20) is approved by the FDA as an aid to the absorption and dispersion of other…
- Trial name
- NCT00883558
- Testing
- Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Halozyme Therapeutics
Type 2 Diabetes Mellitus
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes
This will be a randomized, open label, parallel group, multicenter study. There will be two phases in the study. Phase 1 (Baseline to Week 24) will compare the efficacy and safety of regimens of basal insulin intensified with…
- Trial name
- NCT00467649
- Testing
- pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
- Where
- 37 sites in United States
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome
The investigators are examining the activation of insulin signaling factors in skeletal muscles of human diabetics. The investigators are characterizing the defects in signaling, and are examining the effects of anti-diabetic…
- Trial name
- NCT00690755
- Where
- United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Diabetes, Diabetes Mellitus, Type 2
Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) once daily in insulin naïve subjects with type 2 diabetes…
- Trial name
- BEGIN™ (NCT01326026)
- Testing
- insulin degludec
- Where
- 45 sites in United States, Finland and 2 more
- Volunteers
- 222 people
- Sponsor
- Novo Nordisk A/S
Peripheral Arterial Disease, Type II Diabetes Mellitus
Dietary Nitrate and Exercise to Augment Exercise Training Benefits in Subjects With DM+PAD
The hypothesis of this proposal is that in subjects with Type II diabetes mellitus (T2D) and peripheral arterial disease (PAD) with intermittent claudication (IC), regular consumption of a high nitrate supplement which raises…
- Trial name
- DM+PAD (NCT01785524)
- Testing
- Beetroot Juice (Beet-It Stamina Shot) and Exercise Training
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Duke University
Diabetes Mellitus, Type 2
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with…
- Trial name
- NCT01243424
- Testing
- linagliptin, glimepiride
- Where
- 613 sites in United States, Argentina and 41 more
- Volunteers
- 6,103 people
- Sponsor
- Boehringer Ingelheim
Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
The primary aim is to establish the safety, efficacy and mechanism of action of lanifibranor in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).
- Trial name
- NCT03459079
- Testing
- Lanifibranor
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Florida
Type 2 Diabetes Treated With Insulin
A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes
A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ+ technology in adults with type 2 diabetes using basal-bolus insulin therapy.
- Trial name
- 2IQP (NCT05785832)
- Testing
- t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
- Where
- 21 sites in United States, Canada
- Volunteers
- 319 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Type I, Diabetes Type II
Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment
The purpose of this clinical trial is to perform a limited pilot study to determine the safety and feasibility of DermGEN in the treatment of non-healing diabetic foot ulcers (DFU). This will be a one-arm prospective study.
- Trial name
- NCT02184455
- Testing
- DermGEN
- Where
- 2 sites in Canada
- Volunteers
- 11 people
- Sponsor
- Dr. Paul F. Gratzer
Type 2 Diabetes
Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes
Previous research in our lab and others has established that type 2 diabetes (T2D) is associated with significantly impaired functional exercise capacity, a factor which is potentially associated with an increased risk of…
- Trial name
- Exenatide (NCT01364584)
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes Mellitus
An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)
This is an observational study to compare the effectiveness of dual therapy of Type II diabetes mellitus with metformin + sitagliptin versus metformin + a sulfonylurea in routine clinical practice in France.
- Trial name
- NCT01357135
- Testing
- Metformin, Sitagliptin, Sulfonylurea
- Volunteers
- 3,453 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia, Diabetes Mellitus, Type 2
Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia
The purpose of this study is to determine the efficacy of combining open-label extended release bupropion (flexible dosing up to 450mg target) and naltrexone (37.5mg) versus Bupropion and placebo along with a daily 500 calorie…
- Conditions
- Schizophrenia, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NBC (NCT03132571)
- Testing
- Naltrexone, Bupropion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Yale University
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in Japanese subjects with type 2 diabetes mellitus.
- Trial name
- DUAL™ I Japan (NCT02607306)
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- 76 sites in Japan
- Volunteers
- 819 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3
This study aims to assess the effect and breakdown of lysine administration, specifically examining whether it leads to increased plasma 2-AAA in healthy humans.
- Trial name
- NCT05210504
- Testing
- L-Lysine, Normal Saline
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Diabetes, Diabetes Mellitus, Type 2
Mindfulness IN-home for Diabetes and Sleep Health
The study investigates the effects of a mindfulness intervention on sleep and subsequent cardio-metabolic risk in an adult Atlanta population aged 18 and older.
- Trial name
- MINDS (NCT04160078)
- Testing
- Mindfulness-based stress reduction (MBSR) Intervention
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Type 2 Diabetes Mellitus
Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus
The purpose of this study is to compare the reduction in hemoglobin A1C (A1C) for participants taking saxagliptin in combination with metformin immediate release (IR) versus metformin IR alone.
- Trial name
- NCT00885378
- Testing
- Saxagliptin plus metformin IR
- Where
- 41 sites in United States, Germany and 2 more
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients
This trial is conducted in Africa and Asia. The aim of the trial is to compare patient-adjusted versus physician-adjusted titration of BIAsp 30 combined with metformin in type 2 diabetes patients uncontrolled on NPH insulin.
- Trial name
- NCT01589653
- Testing
- biphasic insulin aspart 30
- Where
- 15 sites in Egypt, Indonesia and 4 more
- Volunteers
- 155 people
- Sponsor
- Novo Nordisk A/S
Hypoglycemia, Type 2 Diabetes
Hypoglycemia (Low Blood Sugar) and the Heart
The risk of hypoglycemia (low blood sugar) associated with the treatment of diabetes increases with age. Hypoglycemia is a common reason for admission to hospital for older patients with diabetes.
- Trial name
- NCT01980914
- Testing
- iPro2 glucose sensor attachment
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University of British Columbia
Diabetes Mellitus, Type 2
Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)
A study of patients with type 2 diabetes and inadequate glycemic control on two or more oral antihyperglycemic agents comparing adding insulin lispro mid mixture to the oral antihyperglycemic agents to adding insulin glargine to…
- Trial name
- IOOX (NCT00377858)
- Testing
- Insulin lispro mid mixture (MM), Insulin glargine
- Where
- 25 sites in Australia, Canada and 5 more
- Volunteers
- 484 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus and Heart Failure
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure
- Trial name
- NCT03152552
- Testing
- LIK066, Empagliflozin
- Where
- 106 sites in United States, Argentina and 22 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals